Long QT syndrome (LQTS) is a hereditary disorder affecting the heart's repolarization process. Dedicated to pushing the boundaries of LQTS diagnostics, our company is at the forefront of developing customized IVD solutions. Through the creation of pioneering genetic and metabolite detection regents/kits and automated diagnostic devices, we strive to confront the intricacies and diagnostic hurdles inherent in LQTS pathology, revolutionizing the detection of this condition.
Introduction to Long Qt Syndrome
Long QT syndrome (LQTS) is a cardiac disorder characterized by an abnormal heart rhythm, specifically a prolonged QT interval on an electrocardiogram (ECG). This condition poses a significant risk of sudden cardiac events, including fainting, seizures, and even sudden death. The incidence of LQTS is estimated to be approximately 1 in 7,000 individuals. The condition can manifest at any age, either from genetic factors or acquired triggers like certain medications or electrolyte imbalances.
Fig. 1 Schematic diagram of the pathogenesis of long QT syndrome (LQTS). (Asatryan, Babken, et al., 2021)
Disease Mechanism of Long Qt Syndrome
The pathogenesis of long QT syndrome (LQTS) primarily revolves around genetic mutations affecting ion channels responsible for cardiac repolarization. These mutations disrupt the delicate balance of ion flow during the heart's electrical cycle, leading to a prolonged QT interval on an electrocardiogram (ECG). This prolonged QT interval predisposes individuals to dangerous arrhythmias, which can result in syncopal episodes, seizures, and sudden cardiac death.
There are several subtypes of LQTS, each associated with specific genetic mutations affecting different ion channels. For example, mutations in genes such as KCNQ1, KCNH2, and SCN5A are commonly implicated in various forms of inherited LQTS.
Acquired factors such as certain medications, electrolyte imbalances, and structural heart abnormalities can further disrupt cardiac repolarization and exacerbate the risk of arrhythmias in individuals predisposed to LQTS.
In Vitro Diagnostic Development for Long Qt Syndrome
In vitro diagnostics (IVD) play a vital role in the detection and diagnosis of long QT syndrome (LQTS), aiding in risk stratification, therapeutic decisions, and ongoing management of affected individuals. Developing advanced IVD tools can facilitate rapid and accurate detection of LQTS. Here are several diagnostic development strategies.
Genetic Testing
Due to LQTS being a rare genetic disorder, genetic testing aids in identifying gene mutations associated with LQTS, such as KCNQ1, KCNH2, and SCN5A. Polymerase chain reaction (PCR) and sequencing technologies are commonly employed to analyze genes related to LQTS for diagnostic confirmation and therapeutic guidance.
Biomarker Testing
Another strategy focuses on biomarker testing of the LQTS disease physiology, such as measuring electrolyte levels and biomarkers such as troponin and B-type natriuretic peptide (BNP). These tests can provide additional diagnostic information and help assess the degree of myocardial stress and damage in individuals with LQTS.
Our Services
At our company, we specialize in tailored in vitro diagnostic (IVD) solutions for long QT syndrome (LQTS). We are dedicated to creating cutting-edge genetic testing kits and metabolite testing kits to enable rapid and portable diagnostics for LQTS. Through innovative diagnostic equipment, our goal is to facilitate efficient and automated detection of LQTS.
IVD Product Development Services
Optional IVD Products
- Genetic Testing Kits
- Electrolyte Detection Kits
- Troponin Detection Kits
- B-type Natriuretic Peptide (BNP) Detection Kits
- Primers and Probes
- DNA Extraction Reagents
- PCR Reagents
- Nucleic Acid Extractor
- PCR Instrument
- DNA Sequencer
- And More
To expedite prompt diagnosis and personalized therapeutics for long QT syndrome (LQTS), we provide point-of-care testing and companion diagnostic development services. These services play a crucial role in enhancing the efficiency and accuracy of LQTS diagnostics, enabling personalized care strategies for affected individuals.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Asatryan, Babken, et al. "Arrhythmic risk during pregnancy and postpartum in patients with long QT syndrome." Herzschrittmachertherapie & Elektrophysiologie 32.2 (2021): 180.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
